TKM-Ebola

TKM-Ebola is an experimental drug to target the Ebola virus. TKM-Ebola is being developed by Tekmira Pharmaceuticals Corporation.

In January 2014, Tekmira commenced a Phase I clinical trial evaluating TKM-Ebola in healthy volunteers to test the safety and how well the drug is tolerated.

In March 2014, The Food and Drug Administration (FDA) granted Tekmira Pharmaceuticals Corporation Fast Track for the development of TKM-Ebola. The FDA's Fast Track is a process to help the development and expedite the review of drugs in order to get important new therapies to patients earlier.

Although it has not been approved, some patients have received experimental drugs, including TKM-Ebola, in hopes that it may help work against Ebola.

TKM-Ebola is part of the drug class:

• DIRECT ACTING ANTIVIRALS